VIP
Neuropeptide with effects on the nervous system, immune function, and circadian rhythm described in animal/in vitro studies. In COVID-19 respiratory failure RCTs, IV aviptadil did not improve 60- or 90-day recovery.
Regulatory status (as of Sept 2026)
Not FDA-approved (aviptadil received expanded-access use for COVID-19 but no approval).
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote4 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
VIP (Vasoactive Intestinal Peptide) is an investigational drug in late-stage (phase 3) human trials. Neuropeptide with effects on the nervous system, immune function, and circadian rhythm described in animal/in vitro studies.
| Half-life | About 2 minutes |
|---|---|
| How it's given in studies | Intranasal or subcutaneous |
| Research stage | Phase 3 |
| Dosing | Published research: No published human dosing detailsAviptadil (synthetic VIP) IV 12-h infusions of 600, 1200, 1800 pmol/kg on days 1-3 (TESICO, COVID-19 respiratory failure).Community-reportedCommunity-reported: 50–100 mcg intranasal, intranasal or subcutaneous |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a natural signaling peptide that acts on receptors found throughout the body. Activates VPAC1 and VPAC2 receptors throughout the body for multiple physiological effects.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedSome users report running VIP (Vasoactive Intestinal Peptide) at 50–100 mcg (intranasal or subcutaneous). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| VIP (Vasoactive Intestinal Peptide) | ~2 minutes | Intranasal or subcutaneous | Phase 3 |
| Cerebrolysin | No published PK data found | IV or IM injection | Approved outside US |
| Cortexin | No published PK data found | Intramuscular injection | Approved outside US |
| Oxytocin | 3-5 minutes (but effects longer) | Intranasal | FDA-approved |
| Thymulin (Zn-FTS) | Unknown | Subcutaneous injection | Preclinical (animal) |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Research category. View All Research Peptides
Immune, Sleep
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.